PRN: World Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Analysis 2017 - Approximately 24 Drug Candidates in Different Stages of Development

27/nov/2017 20.45.11 PR Newswire Turismo Contatta l'autore

World Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Analysis 2017 - Approximately 24 Drug Candidates in Different Stages of Development

 
[27-November-2017]
 

DUBLIN, November 27, 2017 /PRNewswire/ --

The "Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics - Pipeline Analysis 2017" report has been added to Research and Markets' offering.

Research and Markets Logo

The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.

Insights on Pipeline Segments

According to the research findings, most of the drug candidates of CDK inhibitors therapeutics pipeline are being developed to be administered by oral route.

Various Drug Designations for CDK Inhibitors Drug Development

USFDA granted Breakthrough Therapy Designation to a drug candidate of Eli Lilly and Company which is being developed for the treatment of refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This will facilitate the develop! ment and expedite the review of drug candidate for the treatment of refractory HR+ advanced or metastatic breast cancer.

Various Collaborations for CDK Inhibitors Drug Development

Eli Lilly and Company and Boehringer Ingelheim GmbH entered into a collaboration for clinical studies of their drug candidates in combination, in patients diagnosed with HR+, HER2-metastatic breast cancer.

Some of the key players developing drugs as CDK inhibitors for the treatment of various indications include Eli Lilly and Company, Merck & Co., AstraZeneca plc and others.

CDK Inhibitors Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered:

1. Research Background

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1. CDK Inhibitors Overview
4.2. Key Drivers
4.3. Key Barriers
4.4. CDK Inhibitors Pipeline Analysis

5. CDK Inhibitors Therapeutics Pipeline Analysis by Phase (2017)
5.1. Pre-registration/Registration: Drug Profiles
5.2. Phase III: Drug Profiles
5.3. Phase II: Drug Profiles
5.4. Phase I: Drug Profiles
5.5. Pre-Clinical: Drug Profiles
5.6. Discovery: Drug Profiles
5.7. Inactive: Drug Profiles
5.8. Discontinued: Drug Profiles

6. Clinical Trials Analysis
6.1. Clinical Trials by Region
6.2. Clinical Trials by Trial Status

7. Competitive Landscape Analysis
7.1. Key Players Benchmarking
7.2. SWOT Analysis

8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2lnpk9/cyclindependent

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net รจ un servizio offerto da Factotum Srl